United Therapeutics Corporation

Valuation Analysis

About the Company

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal anti

United Therapeutics Corporation Stock at a Glance

United Therapeutics Corporation (UTHR) is currently trading at $545.96 with a market capitalization of $23.2B. The trailing P/E ratio stands at 20.21x, with a forward P/E of 17.18x. The 52-week range spans from $272.12 to $609.35; the current price is 10.4% below the yearly high. Year-over-year revenue growth stands at -1.6%. The net profit margin stands at 40.62%.

💰 Dividend

United Therapeutics Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

13 analysts rate United Therapeutics Corporation (UTHR) on consensus: Buy. The average price target is $665.23, implying +21.85% from the current price. Analyst price targets range from $516.00 to $750.00.

United Therapeutics Corporation: The Investment Case in Detail

United Therapeutics Corporation (UTHR) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 86.58%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 40.62%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Wall Street consensus sits at Buy with an average price target implying roughly 21.85% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue is contracting at -1.6% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

What to Watch Next

• The forward P/E of 17.18x is meaningfully below the trailing 20.21x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 21.85% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (6.04%).

Trading Data

Related Stocks in the Same Sector

Where can I buy United Therapeutics Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.